Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Revenue | $150.5M | $90.1M | $205.1M | $244.7M |
| Cost of revenue | $286.2M | $116.0M | $165.7M | $210.0M |
| Gross profit | −$135.7M | −$25.9M | $39.4M | $34.7M |
| Gross margin | -90.1% | -28.7% | 19.2% | 14.2% |
| R&D | $40.8M | $34.4M | $31.4M | $40.1M |
| Operating income | −$385.2M | −$208.1M | −$219.9M | −$255.5M |
| EBITDA | −$262.3M | −$188.7M | −$157.1M | −$68.4M |
| Net income | −$387.5M | −$208.7M | −$196.3M | −$358.7M |
| Net margin | -257.4% | -231.7% | -95.7% | -146.6% |
| EPS (diluted) | -35.31 | -19.02 | -18.00 | -1.32 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds BRDS.
No tracked institution reports a position in BRDS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-05-19 | 1-for-25reverse |
No one on the platform has traded BRDS yet.
| $321 |
| — |
| IDEXIdeanomics, Inc. | $0.00 | -58.00% | $42143 | — |
| MKULMolekule Group, Inc. | $0.05 | -39.89% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.